Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Up 247.1% in March

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 66,300 shares, a growth of 247.1% from the February 28th total of 19,100 shares. Based on an average daily volume of 4,400,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.9% of the company’s stock are short sold.

Institutional Investors Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Grant Private Wealth Management Inc bought a new position in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 37,193 shares of the company’s stock, valued at approximately $25,000. Grant Private Wealth Management Inc owned approximately 1.00% of Helius Medical Technologies as of its most recent SEC filing. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Stock Performance

Helius Medical Technologies stock opened at $0.42 on Friday. The firm’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.59. The firm has a market cap of $1.57 million, a PE ratio of -0.07 and a beta of 1.62. Helius Medical Technologies has a twelve month low of $0.37 and a twelve month high of $7.19.

Helius Medical Technologies (NASDAQ:HSDT) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.09). The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. Helius Medical Technologies had a negative return on equity of 244.82% and a negative net margin of 1,764.74%.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.